RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF ERLOTINIB OR PLACEBO IN PATIENTS WITH COMPLETELY RESECTED EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTANT NON-SMALL CELL LUNG CANCER (NSCLC)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Non Small Cell Lung Cancer
  • Age: Between 18 years - 100 years
  • Gender: Male or Female
  • Other Inclusion Criteria:

    1.  Patients must have previously registered to A151216, with the result of lung cancer harboring an EGFR exon deletion or L858R mutation.

     

    2.  Patients must have completely resected stage IB, II, or IIIA non-squamous NSCLC with negative margins

     

    3.  Complete recovery from surgery and standard post-operative therapy.


You may not be eligible for this study if the following are true:

  • 1.  Prior or concurrent malignancies within 5 years, except non-melanoma skin carcinoma and in situ carcinoma

     

    2.  History of cornea abnormalities

     

    3.  Pregnancy or Lactation




If you are registered as a volunteer, please log in to contact the study team/express interest in this study.